<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03757078</url>
  </required_header>
  <id_info>
    <org_study_id>20364</org_study_id>
    <nct_id>NCT03757078</nct_id>
  </id_info>
  <brief_title>Study to Find Out How Symptoms Severity Changes During the Standard Course of Treatment With the Cream Relief Pro and Suppositories Relief Pro (Active Ingredients Are Fluocortolone + Lidocaine) in Patients Suffering From Twisted and Bulging Veins in the Rectal Area (Acute Hemorrhoids)</brief_title>
  <official_title>Prospective Multicenter Non-interventional Study of Fluocortolone + Lidocaine Formulation in Patients With Acute Hemorrhoids to Evaluate Changes in Symptoms Severity During the Course of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study researcher wanted to learn more about the changes of biggest twisted and&#xD;
      bulging veins in the rectal area (hemorrhoids) and changes of symptoms during a treatment&#xD;
      period with the cream Relief Pro and suppositories Relief Pro. The study collected&#xD;
      information on the treatment satisfaction of patients and their physicians with the&#xD;
      prescribed treatment by using questionnaires. There were 3 visits at the physician's clinic&#xD;
      for this study: one initial visit and 2 follow-up visits over a period of 2 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2018</start_date>
  <completion_date type="Actual">October 20, 2019</completion_date>
  <primary_completion_date type="Actual">October 20, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of pain (VAS: Visual Analogue Scale)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Pain was measured on a Visual Analogue Scale (VAS) from 0 (No Pain) to 10 (Maximal Pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of bleeding (according to 4-point Likert scale)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>4-point Likert scale consisting of: 1 (None), 2 (Minimal), 3 (Moderate) and 4 (Significant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of pruritus (according to 4-point Likert scale)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of swelling (according to 4-point Likert scale)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity (amount) of discharge (according to 4-point Likert scale)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of sense of discomfort (according to 4-point Likert scale)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall patient satisfaction with treatment (according to 5-point Likert scale)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Likert scale: 1 (Very satisfied), 2 (Satisfied), 3 (Neither satisfied nor dissatisfied), 4 (Dissatisfied) and 5 (Very dissatisfied).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to onset of analgesic effect after the first use of the drug</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of analgesic effect after the first use of the drug</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's adherence to recommendations of the Investigator by PRO</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PRO: Patient Reported Outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Information obtained in the course of questioning about the consumer properties of the study product by PRO</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of hemorrhoids symptoms according to the Sodergren score</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Standardized answer options are given (4 and 5 Likert boxes) and each question gets a score from 0 to 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Size of the largest hemorrhoid node measured during a routine examination</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of swelling when assessed as part of routine examination (according to 4-point Likert scale)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of bleeding when assessed as part of routine examination (according to 4-point Likert scale)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of ReliefPro used based on information provided by the patient to the Investigator</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall satisfaction of Investigator with treatment with Relief Pro according Likert scale from 1 to 5 points as measured on Visits 2 and 3</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1000</enrollment>
  <condition>Acute Hemorrhoids</condition>
  <arm_group>
    <arm_group_label>Patients with acute hemorrhoids</arm_group_label>
    <description>Patients with acute hemorrhoids of 1-2 stage were prescribed Fluocortolone + Lidocaine by a physician. No drug will be provided to Patient by the Investigator, only prescription order, based on International Nonproprietary name (Fluocortolone + Lidocaine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relief Pro cream</intervention_name>
    <description>Relief Pro cream:1.0 mg/gm Fluocortolone + 20 mg/gm Lidocaine; Administration according to clinical practice.</description>
    <arm_group_label>Patients with acute hemorrhoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relief Pro rectal suppositories</intervention_name>
    <description>Relief Pro rectal suppositories: 1.0 mg Fluocortolone + 40 mg Lidocaine; Administration according to clinical practice</description>
    <arm_group_label>Patients with acute hemorrhoids</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult male and female patients with acute hemorrhoids from Russia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male &amp; female patients 18 to 65 years old;&#xD;
&#xD;
          -  Patients with acute hemorrhoids 1 and 2 stage (with thrombosis (external, internal,&#xD;
             mixed), including cases with bleeding);&#xD;
&#xD;
          -  Prescription of fluocortolone + lidocaine as a part of routine clinical practice.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients participating in an investigational program with interventions outside of&#xD;
             routine clinical practice;&#xD;
&#xD;
          -  Hemorrhoid with stage Ëƒ II;&#xD;
&#xD;
          -  Contraindications for use of Relief PRO in the approved product label;&#xD;
&#xD;
          -  Anemia and/or severe/profuse hemorrhoid bleeding;&#xD;
&#xD;
          -  Surgery in perianal region in anamnesis;&#xD;
&#xD;
          -  Concomitant treatment with antibiotics/antiseptics, antithrombotics, antineoplastic&#xD;
             and/or immunosuppressant;&#xD;
&#xD;
          -  Inflammatory bowel disease;&#xD;
&#xD;
          -  Hepatic diseases in severe and acute stages;&#xD;
&#xD;
          -  Colorectal cancer;&#xD;
&#xD;
          -  Purulent-inflammatory diseases of the perianal region and anal canal;&#xD;
&#xD;
          -  Chronic pulmonary diseases in severe and acute stages.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>State Scientific Center of Coloproctology</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 26, 2018</study_first_submitted>
  <study_first_submitted_qc>November 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

